These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 33361512)

  • 21. Neurological toxicities associated with immune-checkpoint inhibitors.
    Touat M; Talmasov D; Ricard D; Psimaras D
    Curr Opin Neurol; 2017 Dec; 30(6):659-668. PubMed ID: 28938341
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Immune Checkpoint Inhibitors and Neuromuscular Adverse Events].
    Suzuki S
    Brain Nerve; 2018 Apr; 70(4):461-466. PubMed ID: 29632293
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune Checkpoint Inhibitors in Patients with Pre-existing Neurologic Autoimmune Disorders.
    Aoun R; Gratch D; Kaminetzky D; Kister I
    Curr Neurol Neurosci Rep; 2023 Nov; 23(11):735-750. PubMed ID: 37870664
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neurological Adverse Events Related to Immune Checkpoint Inhibitors: A Practical Review.
    Zammit F; Seront E
    Pharmaceuticals (Basel); 2024 Apr; 17(4):. PubMed ID: 38675461
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nivolumab and Ipilimumab-induced myositis and myocarditis mimicking a myasthenia gravis presentation.
    Valenti-Azcarate R; Esparragosa Vazquez I; Toledano Illan C; Idoate Gastearena MA; Gállego Pérez-Larraya J
    Neuromuscul Disord; 2020 Jan; 30(1):67-69. PubMed ID: 31839404
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune checkpoint inhibition in patients with inactive pre-existing neuromuscular autoimmune diseases.
    Snavely A; Pérez-Torres EJ; Weber JS; Sandigursky S; Thawani SP
    J Neurol Sci; 2022 Jul; 438():120275. PubMed ID: 35597082
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune Checkpoint Inhibitor-Associated Myositis: A Distinct Form of Inflammatory Myopathy.
    Saygin D; Ghosh N; Reid P
    J Clin Rheumatol; 2022 Oct; 28(7):367-373. PubMed ID: 35696731
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization and management of neurological adverse events during immune-checkpoint inhibitors treatment: an Italian multicentric experience.
    Diamanti L; Picca A; Bini P; Gastaldi M; Alfonsi E; Pichiecchio A; Rota E; Rudà R; Bruno F; Villani V; Galiè E; Vogrig A; Valente M; Zoccarato M; Poretto V; Giometto B; Cimminiello C; Del Vecchio M; Marchioni E
    Neurol Sci; 2022 Mar; 43(3):2031-2041. PubMed ID: 34424427
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune checkpoint inhibitor-induced myocarditis, myositis, myasthenia gravis and transaminitis: a case series and review.
    Wai Siu DH; O'Neill RS; Harris CA; Wang J; Ardolino L; Downton T; Tong M; Hong JH; Chin V; Clingan PR; Aghmesheh M; Soudy H
    Immunotherapy; 2022 May; 14(7):511-520. PubMed ID: 35321560
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Immune Checkpoint Inhibitors-induced Myasthenia Gravis: From Diagnosis to Treatment].
    Yao S; Li X; Nong J; Zhang Y
    Zhongguo Fei Ai Za Zhi; 2020 Aug; 23(8):685-688. PubMed ID: 32752585
    [TBL] [Abstract][Full Text] [Related]  

  • 31. How to diagnose and manage neurological toxicities of immune checkpoint inhibitors: an update.
    Vogrig A; Muñiz-Castrillo S; Farina A; Honnorat J; Joubert B
    J Neurol; 2022 Mar; 269(3):1701-1714. PubMed ID: 34708250
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neurological Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Perspectives and New Development.
    Cheng K; Wang Y; Zhou Y; Xia R; Tang L; Liu J
    Clin Med Insights Oncol; 2021; 15():11795549211056261. PubMed ID: 34866959
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neurological adverse events related to immune-checkpoint inhibitors in Spain: a retrospective cohort study.
    Fonseca E; Cabrera-Maqueda JM; Ruiz-García R; Naranjo L; Diaz-Pedroche C; Velasco R; Macias-Gómez A; Milisenda JC; Muñoz-Farjas E; Pascual-Goñi E; Gállego Perez-Larraya J; Saiz A; Dalmau J; Blanco Y; Graus F; Martinez-Hernandez E;
    Lancet Neurol; 2023 Dec; 22(12):1150-1159. PubMed ID: 37977714
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Neuromuscular Adverse Events].
    Suzuki S
    Gan To Kagaku Ryoho; 2018 Jul; 45(7):1036-1040. PubMed ID: 30042267
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Functional Impairments and Rehabilitation Outcomes of Patients With Immunotherapy-Induced Acute Inflammatory Demyelinating Polyradiculoneuropathy, Myasthenia Gravis, and Myositis.
    Ng AH; Molinares DM; Guo Y; Fu J; Bruera E
    Am J Phys Med Rehabil; 2021 Oct; 100(10):1015-1019. PubMed ID: 33886237
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CNS and PNS manifestation in immune checkpoint inhibitors: A systematic review.
    Khan E; Shrestha AK; Elkhooly M; Wilson H; Ebbert M; Srivastava S; Wen S; Rollins S; Sriwastava S
    J Neurol Sci; 2022 Jan; 432():120089. PubMed ID: 34942546
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of Immune Checkpoint Inhibitor-Induced Myasthenia Gravis Using the US Food and Drug Administration Adverse Event Reporting System.
    Niimura T; Zamami Y; Miyata K; Mikami T; Asada M; Fukushima K; Yoshino M; Mitsuboshi S; Okada N; Hamano H; Sakurada T; Matsuoka-Ando R; Aizawa F; Yagi K; Goda M; Chuma M; Koyama T; Izawa-Ishizawa Y; Yanagawa H; Fujino H; Yamanishi Y; Ishizawa K
    J Clin Pharmacol; 2023 Apr; 63(4):473-479. PubMed ID: 36453166
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma.
    Liao B; Shroff S; Kamiya-Matsuoka C; Tummala S
    Neuro Oncol; 2014 Apr; 16(4):589-93. PubMed ID: 24482447
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibition.
    Pan PC; Haggiagi A
    Curr Oncol Rep; 2019 Nov; 21(12):108. PubMed ID: 31776691
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Immune checkpoint inhibitor-induced anti-striational antibodies in myasthenia gravis and myositis: a case report].
    Sugiyama Y; Esa Y; Watanabe A; Kobayashi J; Suzuki S; Takahashi D
    Rinsho Shinkeigaku; 2021 Sep; 61(9):630-634. PubMed ID: 34433744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.